spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  tipranavir 

 HSMN NewsFeed - 29 Jan 2016
Merck Receives FDA Approval of ZEPATIER(TM) (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 11 Apr 2014
Gilead’s Sovaldi(R) Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease
Biopharmaceuticals
 HSMN NewsFeed - 10 Apr 2014
Gilead Announces Results from Study of Sovaldi(R) for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy
Biopharmaceuticals
 HSMN NewsFeed - 6 Dec 2013
U.S. Food and Drug Administration Approves Gilead’s Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Feb 2010
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 25 Nov 2009
U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 5 Feb 2009
Tibotec Submits Application to U.S. Food and Drug Administration Seeking Traditional Approval for INTELENCE(TM) (etravirine)
Biopharmaceuticals
 HSMN NewsFeed - 7 Feb 2008
New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 6 Feb 2008
Merck's ISENTRESS(R) (raltegravir) Tablets in Combination with other Anti-HIV Medicines Maintained Reductions in HIV-1 Viral Load and Increased CD4 Cell Counts Through 48 Weeks of Therapy in Treatment-Experienced Adults
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 21 Jan 2008
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Biopharmaceuticals FDA HIV/AIDS
 HSMN NewsFeed - 19 Jan 2008
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 6 Jul 2007
New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 5 Jul 2007
New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 14 Jun 2007
Boehringer Ingelheim Initiates SPRING Study of Aptivus(R) (tipranavir) capsules in Diverse Group of Highly Treatment-Experienced HIV Patients
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 1 Mar 2007
Results from Two Phase III Studies on ISENTRESS(TM) (raltegravir, MK-0518), Merck's Oral Investigational Integrase Inhibitor Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI)
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 1 Nov 2006
Panacos Appoints Scott McCallister, M.D., Chief Medical Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 14

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 14 additional stories matching:
tipranavir
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.